This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics' CEO Presents At 30th Annual J.P. Morgan Healthcare Conference (Transcript)

Myriad Genetics, Inc. ( MYGN)

30th Annual J.P. Morgan Healthcare Conference

January 11, 2012 4:30 p.m. ET

Executives

Peter Meldrum - President and Chief Executive Officer

Presentation

Unidentified Speaker

My apologies to cut the lunch time speaker but let me introduce or next company here, it’s Myriad. For those interested in the breakout, it’s going to be across the hallway in the Georgian Room, and let me introduce Pete Meldrum to tell you a little bit more about the story. Pete?

Peter Meldrum

Thank you, and welcome to the Myriad Genetics presentation. Before I begin I would like to point out that I may be making some forward-looking statements, please refer to our SEC filings for risk factors that may cause those statements to differ materially from actual events. Myriad Genetics is the leader in the development and marketing of transforming molecular diagnostic products. Products that assess an individual’s risk for developing cancer later in life, products that help manage specifically to the individual based on their individual genetic makeup, their disease more efficiently. Products that save lives and improve the quality of life.

Myriad has launched nine commercial products to date and we have a strong pipeline of 13 additional products that the company is diligently working on. These products are marketed through our own sales force which consists of 350 individuals throughout the United States, and just recently we have opened our labs in the Europe as we begin to expand internationally. And our products are covered by a strong intellectual property state of 182 issued patents.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs